Summary & Overview
CPT 90283: Immunoglobulin for Passive Immunity
CPT code 90283 represents immunoglobulin products used to provide passive immunity against infections. Immunoglobulin therapies are clinically important for prophylaxis and treatment of immune deficiencies and certain infectious exposures; nationally, these services contribute to outpatient infusion volumes and are central to managing patients who require antibody-based protection. Coverage and payment policies for immunoglobulin administration affect hospital outpatient departments, infusion centers, clinics, and physician offices across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for immunoglobulin use, common sites of service, and the implications for billing and claims processing. The publication summarizes benchmark considerations, typical payer coverage patterns, relevant billing modifiers listed in input data, and where data are not available.
This summary also outlines what to expect in the full publication: coding and billing guidance tied to CPT code 90283, payer-specific coverage considerations, and operational notes for outpatient administration settings. Data not available in the input are identified where applicable.
Billing Code Overview
CPT code 90283 describes immunoglobulin, complex proteins produced by certain cells that provide passive immunity and protect the body from infections. The code applies to services involving immunoglobulin preparation or administration intended to confer passive immune protection.
Service Type: Immune globulin therapy / passive immunization
Typical Site of Service: Outpatient infusion centers, hospital outpatient departments, clinic settings, or physician offices where immunoglobulin products are prepared and administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult or pediatric patient receiving immunoglobulin therapy for passive immunity or immune modulation. Common indications include primary immunodeficiency disorders, certain autoimmune or inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome), or post-exposure prophylaxis when indicated. The clinical workflow begins with a physician evaluation documenting indication, dose calculation (often by weight), and informed consent. Pharmacy prepares the immunoglobulin product and documents lot numbers and expiration. Nursing administers the product intravenously or subcutaneously per protocol, monitors vital signs and infusion tolerance, and documents start/stop times and any adverse reactions. Post-infusion observation and follow-up instructions are provided, and billing staff submits the appropriate code for the immunoglobulin product and any administration services or supplies as separate line items when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Not typically appended; use per payer rules when no specific modifier applies. |
22 | Increased procedural services |